Sep 2026· Advancement of science· 0 citations· 255 references
Medicine
Abstract
ABSTRACT Targeted protein degradation (TPD) redirects endogenous protein‐disposal pathways to selectively eliminate therapeutically relevant proteins. Over the past two decades, this field has progressed from proteolysis‐targeting chimeras (PROTACs) to an expanding repertoire of proteasomal and lysosomal degradation strategies. Recent studies indicate that supramolecular strategies are emerging in TPD, with dynamic noncovalent interactions and ordered assembly shaping degrader construction, delivery, functional integration, or intracellular assembly or activation. Here we organize recent advances into four major modes of supramolecular involvement, encompassing noncovalent modular decoupling of degrader components, delivery‐oriented single‐component self‐assembly, multicomponent co‐assembly for functional integration, and intracellular in situ assembly that generates either persistent local architectures or active degraders following cellular entry. We discuss their applications across proteasomal, endosomal‐lysosomal, and autophagy‐lysosomal degradation pathways. Finally, we discuss translational challenges and emerging opportunities for advancing supramolecular degraders, spanning modular design, strategy diversification, indication selection, systemic biodistribution, intracellular trafficking, safety assessment, and the prospective use of artificial intelligence (AI)‐assisted modeling.
ABSTRACT Lysosome‐targeting chimeras (LYTACs) have emerged as a strategy for eliminating secreted, extracellular, and plasma‐membrane proteins by redirecting them to the endolysosomal system. By coupling target recognition to receptor‐mediated uptake, LYTACs exploit endogenous trafficking pathways to access disease‐ass...
Ke Liu, Xi-Yan Wang, Xiao-Zhen Liu et al.· Advancement of science· 0 citations
This Review provides a framework for selecting disease-matched degradation routes and advancing meTPDs from platform-specific demonstrations towards predictable therapeutic modalities by integrating molecular design, receptor biology, intracellular trafficking, delivery and pharmacodynamic considerations.
Shu-Tong Lin, Hui-Ling Zhou, Jia-Yan Qiu et al.· Advanced Drug Delivery Revie...· 0 citations
Proteolysis‐targeting chimeras (PROTACs) are promising therapeutic agents for targeted protein degradation via the ubiquitin‐proteasome system; however, their clinical application is severely constrained by poor membrane permeability due to high molecular weight and polar surface area, limiting passive diffusion. Eme...
Hua-Hua Chen, Jiayan Jiao, Huiling Yang et al.· MedComm – Biomaterials and A...· 0 citations
This chapter systematically examines three progressive tiers of PROTAC delivery using stimuli-activatable moieties, and highlights how these strategies achieve spatiotemporally controlled, tumor-selective protein degradation while minimizing off-tumor toxicity.
Yi-Jing Dang, Ze-Li Long, Jing Gao et al.· Handbook of Experimental Pha...· 0 citations
The design principles of LTPD platforms are summarized to address the stringent requirements imposed by the LTPD process and may contribute to the rational design of LTPD platforms.
Liheng Liang, Teng Zhang, Xing-Zhen Zhang et al.· TIPS - Trends in Pharmacolog...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.